16 March 2018 - - A Phase 1 clinical trial conducted by the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and using Golden, Colorado-based injection technology specialist PharmaJet's Stratis needle-free injection system has yielded positive interim results,.
The clinical trial is evaluating two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome, which has a 5% to 15% fatality rate and affects tens of thousands of people annually. Currently no vaccine is available.
PharmaJet's delivery device was chosen for this Phase 1 trial after pre-clinical studies with similar vaccines showed significantly higher (tenfold increase) immunogenicity with the needle-free device, as compared to needle and syringe, and comparable results to electroporation.
PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market.
The PharmaJet Needle-free Injectors are safe, fast and easy-to-use. They eliminate needle stick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal.